A N U N T


Seminarul din 28 iulie  DISCUTAT iluminismul francez SEC.xviii.
SEMINARUL VIITOR ESTE LA 29 SEPTEMBRIE CU TEMA idealismul german

                                          A N U N T

Pentru a putea comunica cu noi folositi cu atentie aceste 3 adrese:
1.Adresa revistei de psihiatrie,lunara,"Psychiatry" la situl: aplr-doctorat.blogspot.com (accesibila pentru oricine).
2.Adresa pentru legatura cu redactia revistei, obligatorie pentru a primi invitatia de inscriere in grupul nostru(FORUM):  aplr.doctorat@gmail.com ( atentie la punctul dupa aplr ,nu liniuta)
3.Pentru membrii grupului care au acces la forum si pot si publica pe forum, adresa este: aplr-doctorat1@googlegroups.com
In caz de dificultati dati telefon la 0723156527
Fiti buni si difuzati aceasta stire la toti cei ce vor sa participe la grupul nostru.

Editorial IULIE 2012 - Prof.Dr.A.ROMILA

                                    CU CE RAMINEM

Religia ne spune ca raminem cu speranta si nu luam nimic.
Virsta ne spune ca raminem cu esenta meseriei care este o foaie de
observatie standard si amintirea unor idei mari dela predecesori mari.
Realitatea este indispensabila pentru supravietuire dar nu trebuie
pusa la inima pentruca invinge adesea raul si impostorul, mereu trebuie
rabdat si rugat domnul sa ne dea linistea si sentimentul intregului,
cu libertatea si lirica lui iluzorie. Ramine un imperativ al unirii, al
coerentei, al vitaliatii. Singuratea e de evitat. Facem psihoterapie ca
sa ajutam semenii si sa ne mentinem pe noi. Stim ca ce stim e prea
putin si chiar fals dar comunicam si ne bucuram!

                                                    Prof. A. ROMILA

British Journal of Psychiatry UpDate July

BJP -- Future Table of Contents Alert

A new future TOC for The British Journal of Psychiatry is available online for the issue:

July 2012; Vol. 201, No. 1

This Future Table of Contents is available online at: http://bjp.rcpsych.org/future/201.1.shtml

These articles have been accepted for this issue. Change is possible before publication.

---

Editorials

---

Neuroimaging in psychiatry: bringing neuroscience into clinical practice

M. L. Phillips
The British Journal of Psychiatry 2012 201 (1)

Psychotic symptoms in young people without psychotic illness: mechanisms and meaning

G. K. Murray and P. B. Jones
The British Journal of Psychiatry 2012 201 (1)

Research and the elimination of the stigma of mental illness

P. W. Corrigan
The British Journal of Psychiatry 2012 201 (1)

---

Reappraisal

---

Grief as a psychiatric disorder

R. A. Bryant
The British Journal of Psychiatry 2012 201 (1)

---

Review article

---

Impact of ethnic density on adult mental disorders: narrative review

R. J. Shaw, K. Atkin, L. Becares, C. B. Albor, M. Stafford, K. E. Kiernan, J. Y. Nazroo, R. G. Wilkinson and K. E. Pickett
The British Journal of Psychiatry 2012 201 (1)

---

Papers

---

Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up

C. Galera, M.-P. Bouvard, E. Legarde, G. Michel, E. Touchette, E. Fombonne and M. Melchior
The British Journal of Psychiatry 2012 201 (1)

Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies

I. Kelleher, H. Keeley, P. Corcoran, F. Lynch, C. Fitzpatrick, N. Devlin, C. Molloy, S. Roddy, M. C. Clarke, M. Harley, L. Arseneault, C. Wasserman, V. Carli, M. Sarchiapone, C. Hoven, D. Wasserman and M. Cannon
The British Journal of Psychiatry 2012 201 (1)

White matter abnormalities and illness severity in major depressive disorder

J. Cole, C. A. Chaddock, A. E. Farmer, K. J. Aitchison, A. Simmons, P. McGuffin and C. H. Y. Fu
The British Journal of Psychiatry 2012 201 (1)

Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study

M. J. Firbank, A. Teodorczuk, W. M. Van der Flier, A. A. Gouw, A. Wallin, T. Erkinjuntti, D. Inzitari, L.-O. Wahlund, L. Pantoni, S. Poggesi, G. Pracucci, P. Langhorne and J. T. O'Brien on behalf of the LADIS group
The British Journal of Psychiatry 2012 201 (1)

Magnetic resonance imaging in late-life depression: vascular and glucocorticoid cascade hypotheses

C. E. Sexton, M. Le Masurier, C. L. Allan, M. Jenkinson, L. McDermott, U. G. Kalu, L. L. Hermann, K. M. Bradley, C. E. Mackay and K. P. Ebmeier
The British Journal of Psychiatry 2012 201 (1)

Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics

J. N. Trollor, X. Chen, K. Chitty and P. S. Sachdev
The British Journal of Psychiatry 2012 201 (1)

Filmed v. live social contact interventions to reduce stigma: randomised controlled trial

S. Clement, A. van Nieuwenhuizen, A. Kassam, C. Flach, A. Lazarus, M. de Castro, P. McCrone, I. Norman and G. Thornicroft
The British Journal of Psychiatry 2012 201 (1)

Psychometric properties of the Mental Health Recovery Star

H. Killaspy, S. White, T. L. Taylor and M. King
The British Journal of Psychiatry 2012 201 (1)

 

 

 

 

 

 

BJP -- Future Table of Contents Alert

A new future TOC for The British Journal of Psychiatry is available online for the issue:

July 2012; Vol. 201, No. 1

This Future Table of Contents is available online at: http://bjp.rcpsych.org/future/201.1.shtml

These articles have been accepted for this issue. Change is possible before publication.

---

Editorials

---

Neuroimaging in psychiatry: bringing neuroscience into clinical practice

M. L. Phillips
The British Journal of Psychiatry 2012 201 (1)

Psychotic symptoms in young people without psychotic illness: mechanisms and meaning

G. K. Murray and P. B. Jones
The British Journal of Psychiatry 2012 201 (1)

Research and the elimination of the stigma of mental illness

P. W. Corrigan
The British Journal of Psychiatry 2012 201 (1)

---

Reappraisal

---

Grief as a psychiatric disorder

R. A. Bryant
The British Journal of Psychiatry 2012 201 (1)

---

Review article

---

Impact of ethnic density on adult mental disorders: narrative review

R. J. Shaw, K. Atkin, L. Becares, C. B. Albor, M. Stafford, K. E. Kiernan, J. Y. Nazroo, R. G. Wilkinson and K. E. Pickett
The British Journal of Psychiatry 2012 201 (1)

---

Papers

---

Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up

C. Galera, M.-P. Bouvard, E. Legarde, G. Michel, E. Touchette, E. Fombonne and M. Melchior
The British Journal of Psychiatry 2012 201 (1)

Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies

I. Kelleher, H. Keeley, P. Corcoran, F. Lynch, C. Fitzpatrick, N. Devlin, C. Molloy, S. Roddy, M. C. Clarke, M. Harley, L. Arseneault, C. Wasserman, V. Carli, M. Sarchiapone, C. Hoven, D. Wasserman and M. Cannon
The British Journal of Psychiatry 2012 201 (1)

White matter abnormalities and illness severity in major depressive disorder

J. Cole, C. A. Chaddock, A. E. Farmer, K. J. Aitchison, A. Simmons, P. McGuffin and C. H. Y. Fu
The British Journal of Psychiatry 2012 201 (1)

Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study

M. J. Firbank, A. Teodorczuk, W. M. Van der Flier, A. A. Gouw, A. Wallin, T. Erkinjuntti, D. Inzitari, L.-O. Wahlund, L. Pantoni, S. Poggesi, G. Pracucci, P. Langhorne and J. T. O'Brien on behalf of the LADIS group
The British Journal of Psychiatry 2012 201 (1)

Magnetic resonance imaging in late-life depression: vascular and glucocorticoid cascade hypotheses

C. E. Sexton, M. Le Masurier, C. L. Allan, M. Jenkinson, L. McDermott, U. G. Kalu, L. L. Hermann, K. M. Bradley, C. E. Mackay and K. P. Ebmeier
The British Journal of Psychiatry 2012 201 (1)

Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics

J. N. Trollor, X. Chen, K. Chitty and P. S. Sachdev
The British Journal of Psychiatry 2012 201 (1)

Filmed v. live social contact interventions to reduce stigma: randomised controlled trial

S. Clement, A. van Nieuwenhuizen, A. Kassam, C. Flach, A. Lazarus, M. de Castro, P. McCrone, I. Norman and G. Thornicroft
The British Journal of Psychiatry 2012 201 (1)

Psychometric properties of the Mental Health Recovery Star

H. Killaspy, S. White, T. L. Taylor and M. King
The British Journal of Psychiatry 2012 201 (1)

 

 

 

 

 

 

BJP -- Future Table of Contents Alert

A new future TOC for The British Journal of Psychiatry is available online for the issue:

August 2012; Vol. 201, No. 2

This Future Table of Contents is available online at: http://bjp.rcpsych.org/future/201.2.shtml

These articles have been accepted for this issue. Change is possible before publication.

---

Editorials

---

Antipsychotics: is it time to introduce patient choice?

A. P. Morrison, P. Hutton, D. Shiers and D. Turkington
The British Journal of Psychiatry 2012 201 (2)

Perspectives on the Incredible Years programme: psychological management of conduct disorder

T. Bywater
The British Journal of Psychiatry 2012 201 (2)

Autism spectrum disorder: prevalence and cause may be bound together

E. Simonoff
The British Journal of Psychiatry 2012 201 (2)

Adjustment disorder: implications for ICD-11 and DSM-5

P. Casey
The British Journal of Psychiatry 2012 201 (2)

---

Review article

---

Clinical recognition and recording of alcohol disorders by clinicians in primary and secondary care: meta-analysis

A. J. Mitchell, N. Meader, V. Bird and M. Rizzo
The British Journal of Psychiatry 2012 201 (2)

---

Papers

---

Reducing child conduct problems and promoting social skills in a middle-income country: cluster randomised controlled trial

H. Baker-Henningham, S. Scott, K. Jones and S. Walker
The British Journal of Psychiatry 2012 201 (2)

Migration and autism spectrum disorder: population-based study

C. Magnusson, D. Rai, A. Goodman, M. Lundberg, S. Idring, A. Svensson, I. Koupil, E. Serlachius and C. Dalman
The British Journal of Psychiatry 2012 201 (2)

The extreme male brain revisited: gender coherence in adults with autism spectrum disorder

S. Bejerot, J. M. Eriksson, S. Bonde, K. Carlstrom, M. B. Humble and E. Eriksson
The British Journal of Psychiatry 2012 201 (2)

Childhood cognitive function and adult psychopathology: associations with psychotic and non-psychotic symptoms in the general population

J. H. Barnett, F. McDougall, M. K. Xu, T. J. Croudace, M. Richards and P. B. Jones
The British Journal of Psychiatry 2012 201 (2)

Sexual dysfunction in people with prodromal or first-episode psychosis

T. Reis Marques, S. Smith, S. Bonaccorso, F. Gaughran, A. Kolliakou, P. Dazzan, V. Mondelli, H. Taylor, M. DiForti, P. K. McGuire, R. M. Murray and O. D. Howes
The British Journal of Psychiatry 2012 201 (2)

Adjustment disorders in primary care: prevalence, recognition and use of services

A. Fernandez, J. M. Mendive, L. Salvador-Carulla, M. Rubio-Valera, J. C. Luciano, A. Pinto-Meza, J. M. Haro, D. J. Palao, J. A. Bellon, A. Serrano-Blanco and the DASMAP investigators
The British Journal of Psychiatry 2012 201 (2)

Structure of major depressive disorder in adolescents and adults in the US general population

F. Lamers, M. Burstein, J.-p. He, S. Avenevoli, J. Angst and K. R. Merikangas
The British Journal of Psychiatry 2012 201 (2)

Effect of antidepressive therapy on retinal contrast processing in depressive disorder

E. Bubl, D. Ebert, E. Kern, L. Tebartz van Elst and M. Bach
The British Journal of Psychiatry 2012 201 (2)

 

 

 

 

 

 

BJP -- Future Table of Contents Alert

A new future TOC for The British Journal of Psychiatry is available online for the issue:

July 2012; Vol. 201, No. 1

This Future Table of Contents is available online at: http://bjp.rcpsych.org/future/201.1.shtml

These articles have been accepted for this issue. Change is possible before publication.

---

Editorials

---

Neuroimaging in psychiatry: bringing neuroscience into clinical practice

M. L. Phillips
The British Journal of Psychiatry 2012 201 (1)

Psychotic symptoms in young people without psychotic illness: mechanisms and meaning

G. K. Murray and P. B. Jones
The British Journal of Psychiatry 2012 201 (1)

Research and the elimination of the stigma of mental illness

P. W. Corrigan
The British Journal of Psychiatry 2012 201 (1)

---

Reappraisal

---

Grief as a psychiatric disorder

R. A. Bryant
The British Journal of Psychiatry 2012 201 (1)

---

Review article

---

Impact of ethnic density on adult mental disorders: narrative review

R. J. Shaw, K. Atkin, L. Becares, C. B. Albor, M. Stafford, K. E. Kiernan, J. Y. Nazroo, R. G. Wilkinson and K. E. Pickett
The British Journal of Psychiatry 2012 201 (1)

---

Papers

---

Childhood attention problems and socioeconomic status in adulthood: 18-year follow-up

C. Galera, M.-P. Bouvard, E. Legarde, G. Michel, E. Touchette, E. Fombonne and M. Melchior
The British Journal of Psychiatry 2012 201 (1)

Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies

I. Kelleher, H. Keeley, P. Corcoran, F. Lynch, C. Fitzpatrick, N. Devlin, C. Molloy, S. Roddy, M. C. Clarke, M. Harley, L. Arseneault, C. Wasserman, V. Carli, M. Sarchiapone, C. Hoven, D. Wasserman and M. Cannon
The British Journal of Psychiatry 2012 201 (1)

White matter abnormalities and illness severity in major depressive disorder

J. Cole, C. A. Chaddock, A. E. Farmer, K. J. Aitchison, A. Simmons, P. McGuffin and C. H. Y. Fu
The British Journal of Psychiatry 2012 201 (1)

Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study

M. J. Firbank, A. Teodorczuk, W. M. Van der Flier, A. A. Gouw, A. Wallin, T. Erkinjuntti, D. Inzitari, L.-O. Wahlund, L. Pantoni, S. Poggesi, G. Pracucci, P. Langhorne and J. T. O'Brien on behalf of the LADIS group
The British Journal of Psychiatry 2012 201 (1)

Magnetic resonance imaging in late-life depression: vascular and glucocorticoid cascade hypotheses

C. E. Sexton, M. Le Masurier, C. L. Allan, M. Jenkinson, L. McDermott, U. G. Kalu, L. L. Hermann, K. M. Bradley, C. E. Mackay and K. P. Ebmeier
The British Journal of Psychiatry 2012 201 (1)

Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics

J. N. Trollor, X. Chen, K. Chitty and P. S. Sachdev
The British Journal of Psychiatry 2012 201 (1)

Filmed v. live social contact interventions to reduce stigma: randomised controlled trial

S. Clement, A. van Nieuwenhuizen, A. Kassam, C. Flach, A. Lazarus, M. de Castro, P. McCrone, I. Norman and G. Thornicroft
The British Journal of Psychiatry 2012 201 (1)

Psychometric properties of the Mental Health Recovery Star

H. Killaspy, S. White, T. L. Taylor and M. King
The British Journal of Psychiatry 2012 201 (1)

MDLinx UpDate July

 

Hippocampal Angiogenesis and Progenitor Cell Proliferation Are Increased with Antidepressant Use in Major Depression

Boldrini M et al. – Antidepressants increase human hippocampal neural progenitor cells and angiogenesis selectively in the anterior and mid dentate gyrus. These results raise the possibility of a causal relationship between angiogenesis and neurogenesis, as seen in other proliferating tissues, and support their possible role in the mechanism of action of antidepressants.

 

 

 

 

Role of aripiprazole in treatment-resistant schizophrenia Neuropsychiatric Disease and Treatment, 06/06/12

Mossaheb N et al. ? The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer?term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in clozapine?resistant or clozapine?intolerant patients seems to be worthy of further investigation from the pharmacological and clinical points of view. About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed ?treatment-resistant?. Clozapine is still the gold standard in these cases. However, 40%?70% of patients do not improve sufficiently on clozapine either. In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data. More effort has been made in describing combinations of aripiprazole and clozapine. Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms. Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called ?treatment-intolerant? patients. The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive.

 

 

 

Hippocampal Angiogenesis and Progenitor Cell Proliferation Are Increased with Antidepressant Use in Major Depression Biological Psychiatry, 06/06/12

Boldrini M et al. – Antidepressants increase human hippocampal neural progenitor cells and angiogenesis selectively in the anterior and mid dentate gyrus. These results raise the possibility of a causal relationship between angiogenesis and neurogenesis, as seen in other proliferating tissues, and support their possible role in the mechanism of action of antidepressants.

 

 

 

 

Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis : The Lancet The Lancet - Early Online Publication, 05/23/12

Leucht S et al. – Maintenance treatment with antipsychotic drugs benefits patients with schizophrenia. The advantages of these drugs must be weighed against their side–effects. Methods The authors searched the Cochrane Schizophrenia Group's specialised register for reports published before Nov 11, 2008; and PubMed, Embase, and ClinicalTrials.gov for those before June 8, 2011. They also contacted pharmaceutical companies and searched the reference lists of included studies and previous reviews. Randomised trials of patients with schizophrenia continued on or withdrawn from any antipsychotic drug regimen after stabilisation were eligible. The primary outcome was relapse between 7 and 12 months. The authors also examined safety and various functional outcomes. They used the random effects model and verified results for the primary outcome with a fixed effects model. Heterogeneity was investigated with subgroup and meta-regression analyses. Results The authors identified 116 suitable reports from 65 trials, with data for 6493 patients. Antipsychotic drugs significantly reduced relapse rates at 1 year (drugs 27% vs placebo 64%; risk ratio [RR] 0.40, 95% CI 0.33?0.49; number needed to treat to benefit [NNTB] 3, 95% CI 2?3). Fewer patients given antipsychotic drugs than placebo were readmitted (10% vs 26%; RR 0.38, 95% CI 0.27?0.55; NNTB 5, 4?9), but less than a third of relapsed patients had to be admitted. Limited evidence suggested better quality of life (standardised mean difference -0.62, 95% CI -1.15 to -0.09) and fewer aggressive acts (2% vs 12%; RR 0.27, 95% CI 0.15?0.52; NNTB 11, 6?100) with antipsychotic drugs than with placebo. Employment data were scarce and too few deaths were reported to allow significant differences to be identified. More patients given antipsychotic drugs than placebo gained weight (10% vs 6%; RR 2.07, 95% CI 2.31?3.25), had movement disorders (16% vs 9%; 1.55, 1.25?1.93), and experienced sedation (13% vs 9%; 1.50, 1.22?1.84). Substantial heterogeneity in size of effect was recorded. In subgroup analyses, number of episodes, whether patients were in remission, abrupt or gradual withdrawal of treatment, length of stability before trial entry, first-generation or second-generation drugs, and allocation concealment method did not significantly affect relapse risk. Depot preparations reduced relapse (RR 0.31, 95% CI 0.21?0.41) more than did oral drugs (0.46, 0.37?0.57; p=0.03); depot haloperidol (RR 0.14, 95% CI 0.04?0.55) and fluphenazine (0.23, 0.14?0.39) had the greatest effects. The effects of antipsychotic drugs were greater in two unblinded trials (0.26, 0.17?0.39) than in most blinded studies (0.42, 0.35?0.51; p= 0.03). In a meta-regression, the difference between drug and placebo decreased with study length.

 

 

 

 

 

Role of aripiprazole in treatment-resistant schizophrenia

Neuropsychiatric Disease and Treatment, 06/06/12

Mossaheb N et al. ? The most commonly found beneficial effects are better metabolic outcomes and indicators of the possibility of reducing the clozapine dose. However, other side effects, such as akathisia, are repeatedly reported. Further, none of the studies report longer?term outcomes. In the absence of alternatives, polypharmacy is a common strategy in clinical practice. Combining aripiprazole with clozapine in clozapine?resistant or clozapine?intolerant patients seems to be worthy of further investigation from the pharmacological and clinical points of view.

• About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed ?treatment-resistant?.
• Clozapine is still the gold standard in these cases.
• However, 40%?70% of patients do not improve sufficiently on clozapine either.
• In the search for more efficacious strategies for treatment-resistant schizophrenia, drugs with different pharmacological profiles seem to raise new hopes, but are they valid? The aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia.
• The evidence for aripiprazole monotherapy and for the combination of aripiprazole with psychotropics other than clozapine is scant, and no recommendation can be made on the basis of the currently available data.
• More effort has been made in describing combinations of aripiprazole and clozapine.
• Most of the open-label and case studies as well as case reports have shown positive effects of this combination on overall psychopathology and to some extent on negative symptoms.
• Several reports describe the possibility of dose reduction for clozapine in combination with aripiprazole, a strategy that might help so-called ?treatment-intolerant? patients.
• The findings of four randomized controlled trials with respect to changes in psychopathology seem less conclusive

MedScapen UpDate July

Alzheimer?s Disease: Expert Insights From ICAD 2011 2012-05-08

Most Emailed Articles on Medscape
1.	Menopausal Symptoms: What, When, and How to Treat? Medscape Education
2.	Statins Benefit Patients at Low-Risk for Vascular Disease Heartwire CME
3.	Current Perspectives on Strategies to Prevent Progression of Chronic Kidney Disease Medscape Education
4.	FDA Safety Changes: Azithromycin Linked With Cardiovascular Death Medscape Education
5.	Diabetes and the Kidney - Treatment Strategies for Success Medscape Education

 

 

Alzheimer?s Disease: Expert Insights From ICAD 2011 2012-05-08

Most Emailed Articles on Medscape
1.	Menopausal Symptoms: What, When, and How to Treat? Medscape Education
2.	Statins Benefit Patients at Low-Risk for Vascular Disease Heartwire CME
3.	Current Perspectives on Strategies to Prevent Progression of Chronic Kidney Disease Medscape Education
4.	FDA Safety Changes: Azithromycin Linked With Cardiovascular Death Medscape Education
5.	Diabetes and the Kidney - Treatment Strategies for Success Medscape Education